LXRP - Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17 2021
(TheNewswire)
-
- Lexaria recently expanded its hypertensionR&D program evaluating effectiveness of DehydraTECH-processed CBDto three human clinical studies and two animal studies
Kelowna, British Columbia – TheNewswire - March 11, 2021 –Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or“Lexaria”), a global innovator in drug delivery platforms, today announced that CEO Chris Bunka ispresenting and will be available to meet with investors and analystson a one-on-one basis at the 33 rd Annual VirtualROTH Conference to be held on March 15-17, 2021.
Mr. Bunka will provide an overview of the Company,including its DehydraTECH™ drug delivery technology that improvesthe way active pharmaceutical ingredients enter the bloodstream. Hewill also discuss R&D programs that have been commenced toevaluate delivery effectiveness of DehydraTECH-processed cannabidiol(CBD) for hypertension, antiviral applications for SARS diseases andother infectious diseases, as well as other strategic initiatives. Hispresentation can be viewed by clicking on this link .
The conference will feature presentations from publicand private companies across a variety of industry sectors. Duringprevious events, ROTH has hosted close to 550 participating companiesand attracted more than 5,000 attendees, including institutionalinvestors, analysts, family offices and high-net-worthinvestors.
To learn more and submit a registration request, pleasevisit https://ibn.fm/ROTH2021Registration .
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. DehydraTECH has repeatedly demonstrated since 2016 withcannabinoids and nicotine the ability to increase bio-absorption by upto 5-10x, reduce time of onset from 1 - 2 hours to minutes, and maskunwanted tastes; and is planned to be further evaluated for orallyadministered bioactive molecules, including anti-virals, cannabinoids,vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), andnicotine. Lexaria has licensed DehydraTECH to multiple companiesincluding a world-leading tobacco producer for the development ofsmokeless, oral-based nicotine products and for use in industries thatproduce cannabinoid beverages, edibles, and oral products. Lexariaoperates a licensed in-house research laboratory and holds a robustintellectual property portfolio with 18 patents granted andapproximately 60 patents pending worldwide. For more information,please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Suchforward-looking statements are estimates reflecting the Company's bestjudgment based upon current information and involve a number of risksand uncertainties, and there can be no assurance that the Company willactually achieve the plans, intentions, or expectations disclosed inthese forward-looking statements. As such, you should not placeundue reliance on these forward-looking statements. Factors which could causeactual results to differ materially from those estimated by theCompany include, but are not limited to, government regulation andregulatory approvals, managing and maintaining growth, the effect ofadverse publicity, litigation, competition, scientific discovery, thepatent application and approval process, potential adverse effectsarising from the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related topandemics, and other factors which may be identified from time to timein the Company's public announcements and periodic filings with the USSecurities and Exchange Commission on EDGAR. There is no assurancethat any of Lexaria’s postulated uses, benefits, or advantages forthe patented and patent-pending technology will in fact be realized inany manner or in any part. No statement herein has been evaluated bythe Food and Drug Administration (FDA). Lexaria-associated productsare not intended to diagnose, treat, cure or prevent any disease. Anyforward-looking statements contained in this release speak only as ofthe date hereof, and the Company expressly disclaims any obligation toupdate any forward-looking statements contained herein, whether as aresult of any new information, future events, changed circumstances orotherwise, except as otherwise required by law.
The CSE has not reviewed and does notaccept responsibility for the adequacy or accuracy of this release.
INVESTOR CONTACT:
Copyright (c) 2021 TheNewswire - All rights reserved.